Forte Biosciences, Inc.(FBRX)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Forte Biosciences remains a pre-revenue biotechnology firm heavily reliant on the successful clinical progression of its FB-102 program to justify its current valuation.
• The company faces significant financial headwinds as R&D expenditures have surged to $20.3 million in 2026Q1, leading to a rapid depletion of cash reserves.
• Investors should monitor the company's ability to achieve critical clinical milestones before the current $58.2 million cash balance is exhausted, as the lack of commercial revenue necessitates ongoing, potentially dilutive, capital raises.